[20-F/A] Psyence Biomedical Ltd. Amends Annual Report (Foreign Issuer)

Rhea-AI Filing Summary

Psyence Biomedical Ltd. (PBM) filed Form 20-F/A (Amendment No. 1) for FY ended 31 Mar 2025. The sole purpose is to add the management report on internal control over financial reporting (ICFR) that was inadvertently omitted from the original 25 Jun 2025 filing. No other sections of the annual report have been revised.

Key points:

• Management, including the CEO and CFO, evaluated ICFR and concluded controls were effective as of 31 Mar 2025.
• No material changes in ICFR occurred during the fiscal year.
• The company is a non-accelerated filer & emerging growth company; therefore, an external auditor attestation of ICFR is not required.
• Outstanding common shares at 31 Mar 2025: 568,021.
• Exhibits 12.1 and 12.2 contain re-executed Sarbanes-Oxley §302 certifications; various Inline XBRL files are also included.

The amendment does not affect previously reported financial statements or operational results and should be read in conjunction with the original Form 20-F.

Positive

• Management affirms effective disclosure controls and ICFR, suggesting reliable financial reporting.
• Certifications re-filed under SOX §302, closing a compliance gap without altering prior results.

Negative

• Need for an amendment highlights earlier oversight in governance processes.
• No external auditor ICFR attestation, though permissible, may offer less assurance to some investors.

Insights

Financial Reporting Analyst

TL;DR: Amendment adds missing ICFR report; controls deemed effective—minor procedural fix, limited investor impact.

The filing corrects an administrative oversight by supplying Item 15(b) disclosures. Management’s effective-control conclusion reduces concerns about misstatement risk, and unchanged ICFR indicates stable governance. Because no financial data or guidance is altered, valuation assumptions remain intact. The absence of auditor attestation is normal for a non-accelerated filer. Overall impact is neutral; investors gain comfort that compliance gap is closed without restatements.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 20-F/A

(Amendment No. 1)

(Mark One)

☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended March 31, 2025

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report:

Commission File Number: 001-41937

Psyence Biomedical Ltd.

(Exact name of Registrant as specified in its charter)

Not applicable		Ontario, Canada
(Translation of Registrant’s name into English)		(Jurisdiction of incorporation or organization)

121 Richmond Street West

Penthouse Suite 1300

Toronto, Ontario M5H 2K1

+1 (416) 346-7764

(Address of principal executive offices)

Copy to:

Neil Maresky

121 Richmond Street West

Penthouse Suite 1300

Toronto, Ontario M5H 2K1

+1 (416) 346-7764

(Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common shares, without par value		PBM		The Nasdaq Stock Market LLC
Warrants, each exercisable to purchase one Common Share at an exercise price of $6,874.13 per share		PBMWW		The Nasdaq Stock Market LLC

Securities registered or to be registered pursuant to Section 12(g) of the Act: None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None

The number of the issuer’s outstanding common shares as of March 31, 2025 was 568,021 common shares. 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐   No ☒

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ☐   No ☒

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒   No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒   No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or an emerging growth company. See definition of “accelerated filer,” “large accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	☐	Accelerated filer	☐	Non-accelerated filer	☒
				Emerging growth company	☒

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐

† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP ☐ International Financial Reporting Standards as issue by the International Accounting Standards Board ☒ Other ☐

If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ☐ Item 18 ☐

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Except as otherwise indicated or required by context, references in this Annual Report on Form 20-F (the “Report”) to “we,” “us,” “our,” “Psyence Biomedical” or the “Company” refer to Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada.

Explanatory Note

This Amendment No. 1 to the Annual Report on Form 20-F of Psyence Biomedical Ltd. for the fiscal year ended March 31, 2025 (the “Form 20-F”), originally filed with the Securities and Exchange Commission on June 25, 2025 (the “Original Filing”), is being filed solely to include management’s report on internal control over financial reporting under Item 15(b) that was inadvertently omitted from the Original Filing.

This Amendment also includes re-executed certifications required under Section 302 of the Sarbanes-Oxley Act of 2002 as Exhibits 12.1 and 12.2, dated as of the date of this filing.

This amendment does not reflect events occurring after the date of the Original Filing and does not update or otherwise modify any other disclosures made in the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Filing.

ITEM 15. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

At the end of the period covered by this Report, an evaluation of the effectiveness of the design and operation of the Company’s “disclosure controls and procedures” (as such term is defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act) was carried out by the Company’s principal executive officer (the “CEO”) and principal financial officer (the “CFO”). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon their evaluation, the Company’s CEO and CFO have concluded that, as of the end of the period covered by this Report, the design and operation of the Company’s disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There has been no change in the Company’s internal control over financial reporting during the fiscal year ended March 31, 2025 that has materially affected, or is reasonably likely to materially affect, its internal control over financial reporting.

Management’s Annual Report on Internal Control over Financial Reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officers to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate due to changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of our management, including our principal executive and principal financial officers, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of March 31, 2025. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of March 31, 2025.

Attestation Report of the Registered Public Accounting Firm.

This Report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting, as the Company is not required to obtain such an attestation pursuant to the rules of the Securities and Exchange Commission applicable to non-accelerated filers.

ITEM 19. EXHIBITS

Exhibit No.		Description
12.1*		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
12.2*		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
101.INS*		Inline XBRL Instance Document.
101.SCH*		Inline XBRL Taxonomy Extension Schema Document.
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Filed herewith.

1

SIGNATURE

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this report on its behalf.

Dated: July 25, 2025	PSYENCE BIOMEDICAL LTD.
	By:	/s/ Neil Maresky
	Name:	Neil Maresky
	Title:	Chief Executive Officer

2

0001985062 true FY 0001985062 2024-04-01 2025-03-31 0001985062 dei:BusinessContactMember 2024-04-01 2025-03-31 0001985062 pbm:CommonSharesWithoutParValueMember 2024-04-01 2025-03-31 0001985062 pbm:WarrantsEachExercisableToPurchaseOneCommonShareAtAnExercisePriceOf1150PerShareMember 2024-04-01 2025-03-31 0001985062 2025-03-31 xbrli:shares

FAQ

Why did Psyence Biomedical (PBM) file Form 20-F/A?

The amendment solely adds management’s report on internal control over financial reporting that was omitted from the original filing.

Did the amendment change PBM’s financial statements or guidance?

No. The filing states it does not update or modify the financial data disclosed on 25 Jun 2025.

What was management’s conclusion about PBM’s internal controls?

Management concluded PBM’s disclosure controls and ICFR were effective as of 31 Mar 2025.

Is an external auditor attestation of ICFR included?

No. As a non-accelerated filer, PBM is not required to obtain an auditor attestation report.

How many PBM shares were outstanding at fiscal year-end?

The filing reports 568,021 common shares outstanding as of 31 Mar 2025.

What are PBM’s trading symbols and exchange?

Common shares trade on Nasdaq under PBM; warrants trade under PBMWW.